Category: Press Release

Explore all our news . .

Recent Posts

Synchronoss Announces Strong Messaging Platform Growth in Asia Pacific Fueled by Advanced Messaging

Global Service Providers Utilizing Synchronoss Platforms to Deliver Value-Added Services to Tens of Millions of Subscribers BRIDGEWATER, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced strong growth

BLRX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”), of the important March 6, 2023 lead plaintiff

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed.

BLRX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”), of the important March 6, 2023 lead plaintiff